Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr;8(2):256-265.
doi: 10.21037/jgo.2016.09.07.

Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy

Dae Won Kim  1 , Chetasi Talati  1 , Richard Kim  1
Affiliations
Review

Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy

Dae Won Kim et al. J Gastrointest Oncol. 2017 Apr.

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver cancer with poor prognosis. The incidence of HCC and HCC-related deaths have increased over the last several decades. However, the treatment options for advanced HCC are very limited. Sorafenib remains the only drug approved for systemic treatment for advanced HCC. However, prior to sorafenib era conventional cytotoxic chemotherapies have been studied in advanced HCC. In this review, clinical studies of systemic chemotherapy for advanced HCC will be summarized and discussed.

Keywords: Advanced HCC; chemotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Dr. R Kim receives honorarium from Lilly and Genentech. The other authors have no conflicts of interest to declare.

References

    1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86. 10.1002/ijc.29210 - DOI - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30. 10.3322/caac.21332 - DOI - PubMed
    1. Giannini EG, Farinati F, Ciccarese F, et al. Prognosis of untreated hepatocellular carcinoma. Hepatology 2015;61:184-90. 10.1002/hep.27443 - DOI - PubMed
    1. Roxburgh P, Evans TR. Systemic therapy of hepatocellular carcinoma: are we making progress? Adv Ther 2008;25:1089-104. 10.1007/s12325-008-0113-z - DOI - PubMed
    1. Kato A, Miyazaki M, Ambiru S, et al. Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. J Surg Oncol 2001;78:110-5. 10.1002/jso.1129 - DOI - PubMed